| 國立成功大學 |
2023 |
Real-world experience on intravitreal dexamethasone implant in patients with macular edema scheduled to undergo cataract surgery
|
Lai, C.-C.;Kuo, S.-C. |
| 臺大學術典藏 |
2021-05-06T01:25:13Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; Sun H.-Y.; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; Cheng A.; Ko W.-C.; Cheng S.-H.; CHIEN-CHING HUNG; the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-16T08:36:11Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; Sun H.-Y.; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; ARISTINE CHENG; Ko W.-C.; Cheng S.-H.; Hung C.-C.; the Taiwan HIV Study Group |
| 臺大學術典藏 |
2021-08-20T07:10:55Z |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou B.-H.; HSIN-YUN SUN; Yang C.-J.; Syue L.-S.; Lee Y.-L.; Tang H.-J.; Tsai H.-C.; Lin C.-Y.; Chen T.-C.; Lee C.-Y.; Huang S.-H.; Liu C.-W.; Lu P.-L.; Lin S.-P.; Wang N.-C.; Cheng A.; Ko W.-C.; Cheng S.-H.; Hung C.-C.; the Taiwan HIV Study Group |
| 國立成功大學 |
2021 |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou, B.-H.;Sun, H.-Y.;Yang, C.-J.;Syue, L.-S.;Lee, Y.-L.;Tang, H.-J.;Tsai, H.-C.;Lin, C.-Y.;Chen, T.-C.;Lee, C.-Y.;Huang, S.-H.;Liu, C.-W.;Lu, P.-L.;Lin, S.-P.;Wang, N.-C.;Cheng, A.;Ko, W.-C.;Cheng, S.-H.;Hung, C.-C.;Group, the Taiwan HIV Study |
| 嘉南藥理大學 |
2021 |
Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
|
Liou, Bo-Huang; Sun, Hsin-Yun; Yang, Chia-Jui; Syue, Ling-Shan; Lee, Yu-Lin; Tang, Hung-Jen; Tsai, Hung-Chin; Lin, Chi-Ying; Chen, Tun-Chieh; Lee, Chun-Yuan; Huang, Sung-Hsi; Liu, Chia-Wei; Lu, Po-Liang; Lin, Shih-Ping; Wang, Ning-Chi; Cheng, Aristine; Ko, Wen-Chien; Cheng, Shu-Hsing; Hung, Chien-Ching |
| 臺大學術典藏 |
2020-03-05T06:05:32Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 臺大學術典藏 |
2020-11-03T12:37:44Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
Li-Kai Tsai;Lin H.-J.;Chua S.-K.;Liao P.-C.;Yang Y.-P.;Chou P.-C.;Lee C.-W.;Lin M.-J.;Chen H.-M.;Yeh J.-T.;Li Y.-H.; LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 臺大學術典藏 |
2021-11-26T05:56:35Z |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
LI-KAI TSAI; Lin H.-J.; Chua S.-K.; Liao P.-C.; Yang Y.-P.; Chou P.-C.; Lee C.-W.; Lin M.-J.; Chen H.-M.; Yeh J.-T.; Li Y.-H. |
| 國立成功大學 |
2018-02 |
Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan
|
Tsai;Li-Kai;Lin;Huey-Juan;Chua;Su-Kiat;Liao;Pen-Chih;Yang;Yuan-Po;Chou;Ping-Chen;Lee;Chun-Wei;Lin;Mao-Jen;Chen;Hsi-Ming;Yeh;Jung-Tze;Li;Yi-Heng |
| 國家衛生研究院 |
2024-08-12 |
Real-world insights from comprehensive genomic profiling across multiple cancer types
|
Hung, LJ;Huang, CY;Chen, JS;Huang, WK;Hsu, CC;Fang, YF;Wang, CL;Liu, PC;Yeh, KY;Chang, PH;Chang, JWC;Lin, YC;Huang, SF;Chou, WC |
| 臺大學術典藏 |
2021-08-15T00:08:17Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni, Marisa; CHIH-HSIN YANG; JIN-YUAN SHIH; Peled, Nir; Smit, Egbert F.; Camidge, D. Ross; Arasada, Rajeswara Rao; Oksen, Dina; Boutmy, Emmanuelle; Stroh, Christopher; Johne, Andreas; Carbone, David P.; Paik, Paul K. |
| 臺大學術典藏 |
2021-11-03T02:33:00Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; Yang J.C.-H.; JIN-YUAN SHIH; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-08-10T02:37:40Z |
Real-world insights into patients with advanced NSCLC and MET alterations
|
Bittoni M.; CHIH-HSIN YANG; Shih J.-Y.; Peled N.; Smit E.F.; Camidge D.R.; Arasada R.R.; Oksen D.; Boutmy E.; Stroh C.; Johne A.; Carbone D.P.; Paik P.K. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
|
Kuo Y.-H.; Lu S.-N.; Chen Y.-Y.; Kee K.-M.; Yen Y.-H.; Hung C.-H.; Hu T.-H.; CHIEN-HUNG CHEN; Wang J.-H. |
| 國立交通大學 |
2019-04-03T06:37:18Z |
Real-World Neuroimaging Technologies
|
McDowell, Kaleb; Lin, Chin-Teng; Oie, Kelvin S.; Jung, Tzyy-Ping; Gordon, Stephen; Whitaker, Keith W.; Li, Shih-Yu; Lu, Shao-Wei; Hairston, W. David |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Real-World or Controlled Clinical Trial Data in Real-World Practice
|
Chih-Hsin Yang;Wu T.-H; Wu T.-H; CHIH-HSIN YANG |
| 國立成功大學 |
2024-05-16 |
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
|
Chang;Gee-Chen;Shih;Jin-Yuan;Yu;Chong-Jen;Chao;Heng-Sheng;Yang;Cheng-Ta;Lin;Chien-Chung;Hung;Jen-Yu;Hsiao;Sheng-Yen;Wang;Chin-Chou;Chian;Chih-Feng;Hsia;Te-Chun;Chen;Yuh-Min |
| 國立成功大學 |
2021-07 |
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
|
Tsai;Hong-Ming;Han;Meng-Zhi;Lin;Yih-Jyh;Chang;Ting-Tsung;Chen;Chiung-Yu;Cheng;Pin-Nan;Chuang;Chiao-Hsiung;Wu;I-Chin;Chen;Po-Jun;Kang;Jui-Wen;Chiu;Yen-Cheng;Chiu;Hung-Chih;Chien;Shih-Chieh;Kuo;Hsin-Yu |
| 國立成功大學 |
2021-7 |
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
|
郭欣瑜; Kuo, Shi-Yu; Tsai, Hong-Ming;Han, Meng-Zhi;Lin, Yih-Jyh;Chang, Ting-Tsung;Chen, Chiung-Yu;Cheng, Pin-Nan;Chuang, Chiao-Hsiung;Wu, I-Chin;Chen, Po-Jun;Kang, Jui-Wen;Chiu, Yen-Cheng;Chiu, Hung-Chih;Chien, Shih-Chieh;Kuo, Hsin-Yu |
| 國立成功大學 |
2019-10 |
Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment
|
Su;Po-Lan;Yang;Szu-Chun;Chen;Yi-Lin;Wu;Yi-Lin;Lin;Chia-Ying;Chang;Wei-Yuan;Tseng;Yau-Lin;Lai;Wu-Wei;Ho;Chung-Liang;Lin;Chien-Chung;Su;Wu-Chou |
| 臺大學術典藏 |
2021-09-14T23:18:37Z |
Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015
|
Wang, Chen Yu; Huang, Huai Hsuan; Chen, Ho Min; FEI-YUAN HSIAO; BOR-SHENG KO |
| 臺大學術典藏 |
2022-09-19T03:16:34Z |
Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015
|
Wang C.-Y.; Huang H.-H.; Chen H.-M.; FEI-YUAN HSIAO; Ko B.-S. |
| 臺大學術典藏 |
2020-11-11T00:57:54Z |
Real-world Outcomes of Ultrasonography-guided Interventions in a Tertiary Hospital
|
Liao, Yk;Shyu, Sg;Chueh-Hung Wu; Liao, YK; Shyu, SG; CHUEH-HUNG WU |
| 臺大學術典藏 |
2021-01-21T02:52:29Z |
Real-world outcomes of ultrasonography-guided interventions in a tertiary hospital
|
Liao Y.-K.; SHAW-GANG SHYU; Wu C.-H. |
| 臺大學術典藏 |
2021-11-05T08:01:35Z |
Real-world outcomes of ultrasonography-guided interventions in a tertiary hospital
|
Liao Y.-K.; SHAW-GANG SHYU; Wu C.-H. |
| 臺大學術典藏 |
2021-05-27T02:50:07Z |
Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)
|
Chuah Y.-Y.; Wu D.-C.; Chuah S.-K.; JYH-CHIN YANG; Lee T.-H.; Yeh H.-Z.; Chen C.-L.; Liu Y.-H.; Hsu P.-I. |
| 臺大學術典藏 |
2022-03-04T08:22:44Z |
Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)
|
Chuah Y.-Y.; Wu D.-C.; Chuah S.-K.; JYH-CHIN YANG; Lee T.-H.; Yeh H.-Z.; Chen C.-L.; Liu Y.-H.; Hsu P.-I. |
| 國立臺灣海洋大學 |
2017 |
Real-World RESTful Service Composition: A Transformation-Annotation-Discovery Approach
|
Shang-Pin Ma;Hsuan-Ju Lin;Ci-Wei Lan;Wen-Tin Lee;Ming-Jen Hsu |
| 國立臺灣海洋大學 |
2017 |
Real-World RESTful Service Composition: A Transformation-Annotation-Discovery Approach
|
Shang-Pin Ma;Hsuan-Ju Lin;Ci-Wei Lan;Wen-Tin Lee;Ming-Jen Hsu |
| 國立成功大學 |
2021 |
Real-world results of immune checkpoint inhibitors from the taiwan national health insurance registration system
|
Hsieh, S.-T.;Ho, Ho H.-F.;Tai, H.-Y.;Chien, L.-C.;Chang, H.-R.;Chang, H.-P.;Huang, Y.-W.;Huang, J.-J.;Lien, H.-J.;Huang, L.-Y.;Lee, P.-C. |
| 國立成功大學 |
2021 |
Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
|
Hsieh;S-T;Ho;H-F;Tai;H-Y;Chien;L-C;Chang;H-R;Chang;H-P;Huang;Y-W;Huang;J-J;Lien;H-J;Huang;L-Y;Lee;P-C |
| 臺大學術典藏 |
2020-03-05T06:05:26Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; LI-KAI TSAI; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-05T05:37:43Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Kuo C.-H.;Shin-Joe Yeh;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S.; Lin S.-Y.; Kuo C.-H.; SHIN-JOE YEH; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-02T12:10:28Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y; Kuo C.-H; Yeh S.-J; Tsai L.-K; Liu Y.-B; Huang C.-F; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-04T05:42:30Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y; Kuo C.-H; Yeh S.-J; Tsai L.-K; Liu Y.-B; Huang C.-F; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2020-11-03T11:07:55Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Kuo C.-H.;Yeh S.-J.;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Sung-Chun Tang;Jeng J.-S.; Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2021-07-08T08:19:41Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
SHIN YI LIN; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-11-03T12:37:38Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Jeng J.-S.; Tang S.-C.; Huang C.-F.; Liu Y.-B.; LI-KAI TSAI; Yeh S.-J.; Kuo C.-H.; Lin S.-Y.; Lin S.-Y.;Kuo C.-H.;Yeh S.-J.;Li-Kai Tsai;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S. |
| 臺大學術典藏 |
2021-06-04T06:23:03Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Ching-Hua Kuo;Yeh S.-J.;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S.; Lin S.-Y.; CHING-HUA KUO; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-07-05T07:06:07Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; CHIH-FEN HUANG; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-11-26T05:56:25Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; LI-KAI TSAI; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-12-22T03:53:44Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2020-12-30T07:47:45Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; YEN BIN LIU; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 國立成功大學 |
2020-07-14 |
Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
|
Wu;Pei-Ying;Cheng;Ya-Min;Shen;Meng-Ru;Chen;Yi-Chun;Huang;Yu-Fang;Chou;Cheng-Yang |
| 國立成功大學 |
2020-07-14 |
Real-world Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-line or Relapse Therapy (ROBOT): 8-year Experience
|
黃于芳; Huang, Yu-Fang; Wu, Pei-Ying;Cheng, Ya-Min;Shen, Meng-Ru;Chen, Yi-Chun;Chou, Cheng-Yang |
| 國立成功大學 |
2024 |
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
|
Lee;C, -K.;Yoo;C;Hong;J, Y.;Park;S, J.;Kim;J, W.;Tai;D, W.M.;Kim;H;Korphaisarn;K;Tanasanvimon;S;Chen;S, -C.;Kim;J, W.;Kim;I;Kim;M;Choo;J;Oh;S, -B.;Chen;C, -T.;Bae;W, K.;Kim;H;Huh;S, J.;Yen;C, -J.;Park;S;Lee;D, K.;Chan;L, L.L.;Kang;B;Kang;M;Sundar;R;Choi;H, J.;Chan;S, L.;Chon;H, J.;Lee;M, -A. |
| 國家衛生研究院 |
2025-06 |
Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study
|
Yang, TY;Huang, CT;Liu, PY;Lin, YT;Huang, YS;Chang, PH;Tseng, CH;Chang, YT;Lu, PL;Chen, YC |
| 國立成功大學 |
2018-05-10 |
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
|
Chang;Yi-Sheng;Lee;Wan-Ju;Lim;Chen-Chee;Wang;Shih-Hao;Hsu;Sheng-Min;Chen;Yi-Chian;Cheng;Chia-Yi;Teng;Yu-Ti;Huang;Yi-Hsun;Lai;Chun-Chieh;Tseng;Sung-Huei |
